All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

TGF-β pathway inhibitors

TGF-β pathway inhibitors

The transforming growth factor β (TGF-β) signaling is responsible for the functional inhibition of mesenchymal stromal cells and suppression hematopoietic progenitor cells in MDS and AML. TGF-β pharmacologic blockage, with drugs like luspatercept or sotatercept, can reverse that suppression and promote late-stage erythropoiesis.

|||